Prime Insights

    Drug Pipeline


December 2020 decisions expected from the FDA

November 15, 2020: This synopsis looks ahead to the new drugs expecting an FDA decision in the month of December. December 2020 decisions


Drug pipeline: October 2020

This monthly pipeline wrap up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: October 2020
Specialty pipeline: October 2020


The first biologic treatment for osteoarthritis will trigger some tough talk about trade-offs 

October 20, 2020: If Pfizer/Lilly’s tanezumab is approved (PDUFA in December 2020), will be the first monoclonal antibody nerve growth factor inhibitor for moderate-to-severe osteoarthritis. Read more


November 2020 decisions expected from the FDA

October 15, 2020: This synopsis looks ahead to the new drugs expecting an FDA decision in the month of November. November 2020 decisions


Quarterly drug pipelines: September 2020

These quarterly pipeline wrap-ups include new molecular entity approvals, drugs with approvable status from the FDA, potential blockbuster drugs and the dates of expected FDA approval, names of top selling brand-name drugs with generic availability in the past 12 months and names of top selling brand-name drugs that have patents expiring soon.

Traditional pipeline: September 2020
Specialty pipeline: September 2020


New treatments for a rare disease that affects the optic nerves and spinal cord

September 22, 2020:  Uplinza™ and Enspryng™ are FDA approved to treat neuromyelitis optica spectrum disorder, which can lead to vision loss and paralysis. Prime stays on top of the drug pipeline so our clients don’t fall behind. Read more


October 2020 decisions expected from the FDA

September 11, 2020: This synopsis looks ahead to the new drugs expecting an FDA decision in the month of October. October 2020 decisions


Drug pipeline: August 2020

This monthly pipeline wrap up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: August 2020
Specialty pipeline: August 2020


FDA issues CRL for Biomarin hemophilia gene therapy 

August 20, 2020: The FDA issued a complete response letter (CRL) to Biomarin for Roctavian. The CRL asked for two years of follow-up data on the Phase 3 trial participants.  Since this information will not be available until November 2021, the next FDA review date will most likely not occur until 2022. Read more


September 2020 decisions expected from the FDA

August 14, 2020: This synopsis looks ahead to the new drugs expecting an FDA decision in the month of September. September 2020 decisions


The answer may be growing soon

August 13, 2020:  Looking for 2020 FDA approvals: A diverse group of cell, gene and tissue therapies. Read more 


First SMA treatment approved that can be given at home 

August 10, 2020: Evrysdi™ (risdiplan) will be the third, high cost drug treatment option emerging for spinal muscular atrophy in less than five years; many more are in the pipeline. Read more


Drug pipeline: July 2020

This monthly pipeline wrap up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: July 2020
Specialty pipeline: July 2020


August 2020 decisions expected from the FDA

July 15, 2020: This synopsis looks ahead to the new drugs expecting an FDA decision in the month of August. August 2020 decisions


Cellular therapies continue to evolve

June 30, 2020: CAR-T cell therapy: Removing, re-engineering and reinfusing the patient’s own immune cells, supercharged to become cancer killers. Read more


Quarterly drug pipelines: June 2020

These quarterly pipeline wrap-ups include new molecular entity approvals, drugs with approvable status from the FDA, potential blockbuster drugs and the dates of expected FDA approval, names of top selling brand-name drugs with generic availability in the past 12 months and names of top selling brand-name drugs that have patents expiring soon.

Traditional Pipeline: June 2020
Specialty Pipeline: June 2020


FDA issues CRL for treatment for nonalcoholic fatty liver disease (NASH)

June 29, 2020: Intercept receives complete response letter (CRL) from the FDA for obeticholic acid for the treatment of fibrosis due to NASH. There is currently no drug therapy available for this condition. Read more


July 2020 decisions expected from the FDA

June 15, 2020: This synopsis looks ahead to the new drugs expecting an FDA decision in the month of July. July 2020 decisions


Drug pipeline: May 2020

This monthly pipeline wrap up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: May 2020
Specialty pipeline: May 2020


June 2020 decisions expected from the FDA

May 14, 2020: This synopsis looks ahead to the new drugs expecting an FDA decision in the month of June. June 2020 decisions


Drug pipeline: April 2020

This monthly pipeline wrap up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: April 2020
Specialty pipeline: April 2020


May 2020 decisions expected from the FDA

April 14, 2020: This synopsis looks ahead to the new drugs expecting an FDA decision in the month of May. May 2020 decisions


Gene therapy: A promising future at a high price

April 10, 2020: Gene therapy harnesses the body’s own innate capacity to heal itself and changes the face of health care. Read more


Quarterly drug pipelines: March 2020

These quarterly pipeline wrap-ups include new molecular entity approvals, drugs with approvable status from the FDA, potential blockbuster drugs and the dates of expected FDA approval, names of top selling brand-name drugs with generic availability in the past 12 months and names of top selling brand-name drugs that have patents expiring soon.

Traditional Pipeline: March 2020
Specialty Pipeline: March 2020


April 2020 decisions expected from the FDA

March 13, 2020: This synopsis looks ahead to the new drugs expecting an FDA decision in the month of April. April 2020 decisions.


Drug pipeline: February 2020

This monthly pipeline wrap up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: February 2020
Specialty pipeline: February 2020


March 2020 decisions expected from the FDA

February 14, 2020: This synopsis looks ahead to the new drugs expecting an FDA decision in the month of March. March 2020 decisions.


FDA approves the first treatment for thyroid eye disease (TED)

February 10, 2020: Patients set their sights on relief ahead with Tepezza®. Read more 


Drug pipeline: January 2020

This monthly pipeline wrap up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: January 2020
Specialty pipeline: January 2020


Palforzia is only drug approved to treat peanut allergy in children

January 31, 2020: FDA approved oral Palforzia™ for mitigating allergic reactions that occur with accidental exposure to peanut, although peanut avoidance remains the first and best defense. Months later, in August 2020, the FDA issued a complete response letter (CRL) to DBV Technologies for its peanut desensitizing patch, Viaskin™. The FDA asked for modifications to the patch, as well as an additional study. Peanut desensitizer overview


Reyvow – approved and ready to launch

Jan. 31, 2020: Reyvow has received a controlled substance designation (V) from the DEA and is now ready to launch. Reyvow was approved by the FDA in October 2019, as the first serotonin receptor agonist to target the 5-HT1F receptor. Reyvow overview


FDA issues its first approval for an oral CGRP formulation for migraine 

January 25, 2020: Ubrelvy™ brings a new treatment option (oral) to a new drug class (CGRP) for patients with migraine.  Prime stays on top of the drug pipeline so our clients don’t fall behind. Read more


Breakthrough therapy for cystic fibrosis

January 20, 2020: Trikafka’s triple combination therapy (elexacaftor/ivacaftor/tezacaftor) may cover 90% of patients with cystic fibrosis. Read more


February 2020 decisions expected from the FDA

January 17, 2020: This synopsis looks ahead to the new drugs expecting an FDA decision in the month of February. February 2020 decisions


Quarterly drug pipelines: December 2019

These quarterly pipeline wrap-ups include new molecular entity approvals, drugs with approvable status from the FDA, potential blockbuster drugs and the dates of expected FDA approval, names of top selling brand-name drugs with generic availability in the past 12 months and names of top selling brand-name drugs that have patents expiring soon.

Traditional pipeline: December 2019
Specialty pipeline: December 2019


January 2020 decisions expected from the FDA

December 13, 2019: This synopsis looks ahead to the new drugs expecting an FDA decision in the month of January. January 2020 decisions


Zyntelgo has approval in Europe

Dec. 9, 2019: Still waiting for FDA approval. Only a few thousand people worldwide might need gene therapy Zyntelgo for the most severe form of transfusion-dependent beta-thalassemia.  Zyntelgo overview


Drug pipeline: November 2019

This monthly pipeline wrap up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: November 2019
Specialty pipeline: November 2019


December 2019 decisions expected from the FDA

December 13, 2019: This synopsis looks ahead to the new drugs expecting an FDA decision in the month of December. December 2019 decisions


Drug pipeline: October 2019

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: October 2019
Specialty pipeline: October 2019


November 2019 decisions expected from the FDA

Oct. 15, 2019: This synopsis looks ahead to the new drugs expecting an FDA decision in the month of November. November 2019 decisions


Quarterly drug pipelines: September 2019

These quarterly pipeline wrap-ups include new molecular entity approvals, drugs with approvable status from the FDA, potential blockbuster drugs and the dates of expected FDA approval, names of top selling brand-name drugs with generic availability in the past 12 months and names of top selling brand-name drugs that have patents expiring soon.

Traditional pipeline: September 2019
Specialty pipeline: September 2019


October 2019 decisions expected from the FDA

Sept.15. 2019: This synopsis looks ahead to the new drugs expecting an FDA decision in the month of October. October 2019 decisions


Drug pipeline: August 2019

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: August 2019
Specialty pipeline: August 2019


September 2019 decisions expected from the FDA

Aug. 15, 2019: This synopsis looks ahead to the new drugs expecting an FDA decision in the month of September. September 2019 decisions


Drug pipeline: July 2019

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: July 2019
Specialty pipeline: July 2019


August 2019 decisions expected from the FDA

July 15, 2019: This synopsis looks ahead to the new drugs expecting an FDA decision in the month of August. August 2019 decisions


Quarterly drug pipelines: June 2019

These quarterly pipeline wrap-up include new molecular entity approvals, drugs with approvable status from the FDA, potential blockbuster drugs and the dates of expected FDA approval, names of top selling brand-name drugs with generic availability in the past 12 months and names of top selling brand-name drugs that have patents expiring soon.

Traditional pipeline: June 2019
Specialty pipeline: June 2019


New indication approved for neuromyelitis optica spectrum disorder (NMOSD): 

June 27, 2019: Soliris (eculizumab) was approved for the new indication.  Soliris (eculizumab)


July 2019 decisions expected from the FDA

June 15, 2019: This synopsis looks ahead to the new drugs expecting an FDA decision in the month of July. July 2019 decisions


Drug pipeline: May 2019

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: May 2019
Specialty pipeline: May 2019


What does it mean now that Zolgensma is approved?

May 24, 2019: At Prime, we get ahead of drug trends to prepare for new, high-cost drugs entering the market. Zolgensma® (onasemnogene abeparvovec-xioi) was approved May 24, 2019Zolgensma® (onasemnogene abeparvovec-xioi)


Drug pipeline: April 2019

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: April 2019
Specialty pipeline: April 2019


Quarterly drug pipeline: March 2019

These quarterly pipeline wrap-ups include new molecular entity approvals, drugs with approvable status from the FDA, potential blockbuster drugs and the dates of expected FDA approval, names of top selling brand-name drugs with generic availability in the past 12 months and names of top selling brand-name drugs that have patents expiring soon.

Traditional pipeline: March 2019
Specialty pipeline: March 2019


New drug approved for treatment-resistant depression (TRD)

March 6, 2019: Spravato (esketamine) nasal spray was approved for treatment-resistant depression. Staying on top of the drug pipeline so our clients don’t fall behind.  Spravato (esketamine)  


Drug pipeline: February 2019

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: February 2019
Specialty pipeline: February 2019


Drug pipeline: January 2019

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: January 2019
Specialty pipeline: January 2019


Infographic: Rheumatoid arthritis December 2018

Dec. 2018:  44% of members newly diagnosed with RA do not start on disease modifying antirheumatic drugs (DMARDS) in their first year, as recommended by treatment guidelines. What does this mean for their treatment path? Infographic 


Quarterly drug pipeline: December 2018

These quarterly pipeline wrap-ups include new molecular entity approvals, drugs with approvable status from the FDA, potential blockbuster drugs and the dates of expected FDA approval, names of top selling brand-name drugs with generic availability in the past 12 months and names of top selling brand-name drugs that have patents expiring soon.

Traditional pipeline: December 2018
Specialty pipeline: December 2018


Drug pipeline: November 2018

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: November 2018
Specialty pipeline: November 2018


Drug pipeline: October 2018

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: October 2018
Specialty pipeline: October 2018


A new option opens up for severe asthma

Nov. 2018: Dupixent (dupilumab) received this FDA approval for an additional indication in 2018 as an add-on maintenance treatment for severe asthma on October 20, 2018. Dupixent (dupilumab)


Quarterly drug pipeline: September 2018

These quarterly pipeline wrap-ups include new molecular entity approvals, drugs with approvable status from the FDA, potential blockbuster drugs and the dates of expected FDA approval, names of top selling brand-name drugs with generic availability in the past 12 months and names of top selling brand-name drugs that have patents expiring soon.

Traditional pipeline: September 2018
Specialty pipeline: September 2018


It’s an entire new class of drugs for migraine sufferers

Oct. 2018 The new class of drugs is called selective calcitonin gene-related peptide (CGRP) antagonists for the prevention of migraine. Emgality® (galcanezumab-gnlm) is one of three CGRPs approved in 2018, on September 27, 2018.  Emgality® (galcanezumab-gnlm) 


It’s an entire new class of drugs for migraine sufferers

The new class of drugs is called selective calcitonin gene-related peptide (CGRP) antagonists for the prevention of migraine. Ajovy® (fremanezumab-vfrm) is one of three CGRPs approved in 2018, on September 14, 2018. Ajovy® (fremanezumab-vfrm) 


Drug pipeline: August 2018

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: August 2018
Specialty pipeline: August 2018


Drug pipeline: July 2018

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: July 2018
Specialty pipeline: July 2018


Quarterly drug pipeline: June 2018

These quarterly pipeline wrap-ups include new molecular entity approvals, drugs with approvable status from the FDA, potential blockbuster drugs and the dates of expected FDA approval, names of top selling brand-name drugs with generic availability in the past 12 months and names of top selling brand-name drugs that have patents expiring soon.

Traditional pipeline: June 2018
Specialty pipeline: June 2018


New drug treats Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS)

Epidiolex® (cannabidiol - CBD) treats two rare, drug-resistant forms of epilepsy. We’ve been following it since it began clinical trials. Epidiolex® (cannabidiol - CBD) was approved on June 27, 2018Epidiolex® (cannabidiol - CBD) 


Drug pipeline: May 2018

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: May 2018
Specialty pipeline: May 2018


It’s an entire new class of drugs for migraine sufferers

The new class of drugs is called selective calcitonin gene-related peptide (CGRP) antagonists for the prevention of migraine. Aimovig® (erenumab-aooe) is one of three CGRPs approved in 2018, approved on May 17, 2019. Aimovig® (erenumab-aooe) 


Drug pipeline: April 2018

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: April 2018
Specialty pipeline: April 2018


Quarterly drug pipeline: March 2018

These quarterly pipeline wrap-ups include includes new molecular entity approvals, drugs with approvable status from the FDA, potential blockbuster drugs and the dates of expected FDA approval, names of top selling brand-name drugs with generic availability in the past 12 months and names of top selling brand-name drugs that have patents expiring soon.

Traditional pipeline: March 2018
Specialty pipeline: March 2018


Drug pipeline: February 2018

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: February 2018
Specialty pipeline: February 2018


Drug pipeline: January 2018

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: January 2018
Specialty pipeline: January 2018


Drug pipeline: December 2017

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: December 2017
Specialty pipeline: December 2017


Drug pipeline: November 2017

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: November 2017
Specialty pipeline: November 2017


Drug pipeline: October 2017

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: October 2017
Specialty pipeline: October 2017


Drug pipeline: September 2017

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: September 2017
Specialty pipeline: September 2017


Drug pipeline: August 2017

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: August 2017
Specialty pipeline: August 2017


Drug pipeline: July 2017

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: July 2017
Specialty pipeline: July 2017


Drug pipeline: June 2017

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: June 2017
Specialty pipeline: June 2017


Drug pipeline: May 2017

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: May 2017
Specialty pipeline: May 2017


Drug pipeline: April 2017

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: April 2017
Specialty pipeline: April 2017


Drug pipeline: March 2017

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: March 2017
Specialty pipeline: March 2017


Drug pipeline: February 2017

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: February 2017
Specialty pipeline: February 2017


Drug pipeline: January 2017

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: January 2017
Specialty pipeline: January 2017


Drug pipeline: December 2016

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: December 2016
Specialty pipeline: December 2016


Drug pipeline: November 2016

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: November 2016
Specialty pipeline: November 2016


Infographic: Drug pipeline profile: Duchenne muscular dystrophy

Nov. 11, 2016: New  therapies for this rare disease are in the pipeline, and they could have a big impact on drug costs — up to $4.57 Nper member per year.

DMD and what’s on the horizon


Drug pipeline: October 2016

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: October 2016
Specialty pipeline: October 2016


Drug pipeline: September 2016

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: September 2016
Specialty pipeline: September 2016


Drug pipeline: August 2016

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: August 2016
Specialty pipeline: August 2016


Drug pipeline: July 2016

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: July 2016
Specialty pipeline: July 2016


Drug pipeline: June 2016

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: June 2016
Specialty pipeline: June 2016


Drug pipeline: May 2016

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: May 2016
Specialty pipeline: May 2016


Drug pipeline: April 2016

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: April 2016
Specialty pipeline: April 2016


Drug pipeline: March 2016

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: March 2016
Specialty pipeline: March 2016


Drug pipeline: February 2016

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: February 2016
Specialty pipeline: February 2016


Drug pipeline: January 2016

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: January 2016
Specialty pipeline: January 2016


Drug pipeline: December 2015

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: December 2015
Specialty pipeline: December 2015


Drug pipeline: November 2015

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: November 2015
Specialty pipeline: November 2015


Drug pipeline: October 2015

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: October 2015
Specialty pipeline: October 2015


Drug pipeline: September 2015

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: September 2015
Specialty pipeline: September 2015